Apogee Therapeutics, Inc. (NASDAQ:APGE) is one of the 10 Stocks Crash Hard Alongside Wall Street. Apogee Therapeutics fell by ...

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

Shares of Apogee Therapeutics Inc. (NASDAQ:APGE) soared 24% in Monday’s session following encouraging results from its Phase ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...

Shares of Apogee Therapeutics, Inc. APGE +46.5% + Free Alerts rose sharply in today's pre-market trading after the company ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Apogee Therapeutics shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment. Shares traded 36% higher ahead of the morning ...

Apogee Therapeutics said its antibody treatment alleviated signs and symptoms of atopic dermatitis far more than a placebo — achieving the efficacy goals of a clinical trial.

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...